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Abstract
Background: Given the high rate of pregnancy and perinatal complications recently observed in patients with
polycystic ovary syndrome (PCOS) and the lack of data on the serum variations in androgens and insulin sensitivity
indexes in pregnant women with PCOS, the current study was aimed to assess these changes and their potential
effect on pregnancy outcomes in a population of women with PCOS.
Methods: Forty-five pregnant patients with ovulatory PCOS (PCOS group) and other 42 healthy pregnant women
(control group) were studied assaying serum androgen levels and insulin sensitivity indexes throughout pregnancy
serially, and recording obstetrical outcomes.
Results: Serum androgen levels and insulin resistance indexes were significantly (p < 0.05) higher in PCOS than in
control group at study entry, these differences were sustained throughout pregnancy, and their changes resulted
significantly (p < 0.05) different between PCOS and control group. In PCOS patients, women who had a
complicated pregnancy showed serum androgen levels and insulin sensitivity indexes significantly (p < 0.05) worse
in comparison to subjects without any pregnancy and/or neonatal complications.
Conclusions: PCOS patients have impaired changes in serum androgen levels and insulin sensitivity indexes during
pregnancy. These alterations could be implicated in the pregnancy and neonatal complications frequently
observed in women affected by PCOS.
Background
Polycystic ovary syndrome (PCOS) is a heterogeneous
disorder characterized by biochemical alteration, i.e.
hyperandrogenism and insulin resistance, and ovarian
impairment, resulting in chronic anovulation. The
chronic anovulation is not the only factors influencing
the reduced reproductive chances in PCOS patients. In
fact, an increased incidence of complications throughout
pregnancy was also observed in PCOS women after
meta-analytic analysis [1].
Recently, we confirmed in a well selected population
of PCOS patients an increased relative risk (RR) for
complicated pregnancy [1.7, 95% confidence interval
(CI) 1.12-2.96] with a total incidence of adverse out-
comes of 31.4% [2]. In addition, the risk for adverse out-
comes in PCOS resulted significantly related to ovarian
dysfunction and biochemical hyperandrogenism [3].
Moreover, our previous study evaluated only baseline
androgen levels in PCOS population and no relationship
with insulin sensitivity indexes was investigated [3]. In
addition, to the moment, no report was aimed to evalu-
ate the dynamic of the hormonal and metabolic patterns
in pregnant women with PCOS.
The current study is a parallel analysis of a larger pre-
viously published clinical report [2] aimed to study
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throughout pregnancy in PCOS patients, and their effect
on pregnancy outcomes.
Methods
The study was approved by the Institutional Review
Board (IRB) of the Department of Obstetrics and Gyne-
cology of the University “Magna Graecia” of Catanzaro.
The protocol was carefully explained to each subject
before entering the study and their written consent was
obtained.
Between February 2003 and April 2008, subjects with
ovulatory PCOS (PCOS group) and age- and body
mass index (BMI)-matched healthy primigravidas were
initially enrolled in a wider study protocol [2]. Ovula-
tory PCOS was diagnosed before pregnancy and con-
firmed at study entry according to the presence of
polycystic ovaries (PCO) and clinical/biochemical
hyperandrogenism without chronic oligo-anovulation
[4], while the healthy state of the controls was deter-
mined by their medical history, physical and pelvic
examination, complete blood chemistry, and transvagi-
nal ultrasonography [2].
Age > 35 years, obesity (BMI > 30 Kg/m2), multiple
pregnancies, gestational age higher than 7 weeks as
assessed by crown-rump length (CRL) measurement,
pre-malignancies or malignancies, medical conditions or
other concurrent medical illnesses, cigarettes’ smoking,
drug/alcohol use, organic pelvic disease, uterine malfor-
mations, previous pelvic surgery, no compliance to our
study-protocol, and current or previous (within the last
six months) use of any hormonal and/or anti-diabetic
and/or fertility drugs were considered as exclusion cri-
teria for both cases and controls.
Each subject received folic acid (0.4 mg daily) and was
instructed to follow usual diet and physical activity
throughout the study.
Serial clinical, biochemical and ultrasonographic
assessments for mother and/or fetal wellbeing monitor-
ing were performed during the study according to our
schedule [2,3].
Clinical evaluation consisted in obstetric examination,
Papanicolau smear test (at study entry alone), Ferriman-
Gallwey score [5] calculation, anthropometric measure-
ments [including height, weight, BMI and waist-to-hip
ratio (WHR)], heart rate (HR) and blood pressure (BP)
assessments. In order to evaluate the subjects’ physical
activity, job, daily activities, and family history of com-
plicated pregnancies specific questionnaires were com-
pleted by each woman.
Each subject underwent serial drawn blood samples to
evaluate serum androgen levels and insulin sensitivity.
All blood samples were obtained in the morning
between 08.00 h and 09.00 h after an overnight fasting
and resting in bed at study entry (within the 7
th week of
gestation), and at the 12
th,t h e2 0
th and the 32
nd weeks
of gestation. Particularly, total serum testosterone (T),
androstenedione (A), dehydroepiandrosterone sulfate
(DHEAS), and sex-hormone binding globulin (SHBG)
were assayed. Glucose and insulin concentrations were
assayed at fasting and, only at baseline, after oral glucose
tolerance test (OGTT). The area under curve (AUC) for
glucose and insulin, as well as the homeostasis model of
assessment (HOMA) [fasting glucose (mmol/L) × fasting
insulin (μU/mL)⁄22.5] [6], the fasting glucose-to-insulin
ratio (GIR) (mg/10-4U) [7], and the free androgen index
(FAI) [T (nmol/l)/SHBG × 100]) [8] were calculated in
each subject.
All plasma hormone concentrations were measured by
specific radioimmunoassay (RIA), whereas SHBG levels
using an immunoradiometric assay (IRMA) [9]. Overall,
intra- and inter-assay coefficients of variation (CV) were
less than 10%.
Pregnancy/perinatal outcomes were evaluated in each
subject as already detailed [2].
Statistical analysis
The Kolmogorov-Smirnov statistic with a Lilliefors sig-
nificance level was used for testing normality. Since our
data resulted normally distributed, results were
expressed as mean ± standard deviation (SD). Continu-
ous variables were analyzed with the one-way analysis of
variance (ANOVA) and ANOVA for repeated measures
with Bonferroni test for the post hoc analysis.
For categorical variables, the Pearson chi-square test
was performed; Fisher’se x a c tt e s tw a su s e df o rt h ef r e -
quency tables when more than 20% of the expected
values were lower than five.
Variations (Δ) in serum T, A, DHEAS, SHBG, and
fasting insulin levels, and in HOMA, GIR and FAI were
calculated at each follow-up in both groups for the over-
all population, these data were also adjusted for age and
BMI and analyzed in sub-populations distinguished on
the basis of the presence/absence of adverse pregnancy
and neonatal outcomes.
Data were analyzed using the per-protocol analysis.
The level of statistical significance was set at p <0 . 0 5
for all statistical analyses. The Statistics Package for
Social Sciences (SPSS 14.0.1, 18 Nov 2005; SPSS Inc.,
Chicago, IL) was used for all calculations.
Results
Forty-five and 42 subjects from the PCOS and control
group, respectively, were included in the final analysis.
In fact, part of the original study population (20 subjects
for the PCOS group and 22 subjects for the control
group) did not give their consent to participate to the
current study protocol, while in 8 and 9 subjects from
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follow-up visit were not available for the analysis.
The main clinical data from PCOS and control group
a ts t u d ye n t r ya r es h o w ni nT a b l e1 .T h eW H Ra n d
the Ferriman-Gallwey score, such as the AUCglucose,
AUCinsulin,a n dA U C glucose/AUCinsulin were significantly
(p < 0.05) higher in the PCOS than in the control
group (Table 1). Similarly, serum levels of T, A, and
DHEAS were significantly (p < 0.05) higher in the
PCOS than in the control group (Figure 1). FAI and
SHBG (Figure 2), such as fasting insulin concentra-
tions, HOMA, and GIR (Figure 3) also differed signifi-
cantly (p < 0.05) between groups.
At each follow-up assessment, serum T, A and DHEAS
levels were significantly (p < 0.05) higher in PCOS than
in control group (Figure 1). Significant (p <0 . 0 5 )
increases at the 20
th and 32
nd weeks of gestation were
observed in T and DHEAS levels, in the PCOS group
alone, whereas they resulted unchanged in the control
group. In both PCOS and control groups, A levels
resulted unchanged throughout pregnancy (Figure 1).
SHBG levels and FAI were significantly (p <0 . 0 5 )
lower and higher, respectively, in PCOS than in control
group (Figure 2). In both PCOS and control groups,
SHBG levels were significantly (p <0 . 0 5 )i n c r e a s e da t
each follow-up visit, while FAI resulted significantly (p <
0.05) reduced from 20
th weeks of gestation (Figure 2).
Fasting insulin levels, GIR and HOMA were signifi-
cantly (p < 0.05) different between PCOS and control
groups at each follow-up assessment. In PCOS group,
fasting insulin levels and HOMA were significantly (p <
0.05) increased at the 20
th and 32
nd weeks of gestation,
whereas GIR significantly (p < 0.05) reduced at the same
follow-ups. Conversely, no significant change during
pregnancy was observed in any insulin sensitivity index
in the control group.
Table 2 shows the variations in T, A, DHEAS, SHBG
and fasting insulin levels, and in HOMA, GIR and FAI
in PCOS and control groups. Significant differences (p <
0.05) were observed in the variations in T, DHEAS,
SHBG and fasting insulin levels, and HOMA, GIR and
FAI between PCOS and control groups at each follow-
up assessment. No further significant difference was
observed between two groups.
A total of 13 out of 45 (28.9%) from the PCOS group
a n d4o u to f4 2( 9 . 5 % )f r o mt h ec o n t r o lg r o u p( p =
0.044) had adverse pregnancy and/or neonatal out-
comes. In particular, pre-eclampsia occurred in 6 and 1
subjects from PCOS and control group, respectively;
whereas a pregnancy-induced hypertension was diag-
nosed in 7 and 3 subjects from PCOS and control
group, respectively. Significant differences between
groups were observed in fetal birth weight (3121.4 ±
762.1 vs. 3459.8 ± 673.2 g for PCOS and control groups,
respectively; p = 0.008), while gestational age at delivery
was not significantly different between groups (37.5 ±
2.7 vs. 38.9 ± 2.2 wks for PCOS and control groups,
respectively; p = 0.641).
I nT a b l e2a r es h o w nt h ev a r i a t i o n si nT ,A ,D H E A S ,
SHBG and fasting glucose and insulin levels, and in
HOMA, GIR and FAI in the sub-populations distin-
guished on the basis of the presence/absence of adverse
pregnancy/perinatal outcomes and adjusted for age and
BMI. A significant (p < 0.05) difference in serum T,
DHEAS, SHBG, and fasting insulin levels, and in
HOMA, GIR and FAI was observed between patients
who had and who had not adverse pregnancy/perinatal
outcomes only in PCOS group, whereas any difference
was observed in healthy controls (Table 2).
Discussion
Based on previous results [1,2], PCOS should be consid-
ered a heterogeneous disorder related to a higher risk
for complicated pregnancy. In particular, the risk for
any adverse pregnancy/neonatal outcome seemed to be
affected by specific PCOS features, i.e. ovarian dysfunc-
tion and biochemical hyperandrogenism, whereas no
significant effect was detected for clinical hyperandro-
genism and ovarian morphology [3]. However, the
dynamic of both androgens and insulin sensitivity
indexes during pregnancy and their relationship with
complications were not investigated [3].
Considering the study protocol, elevated androgen
levels were observed in PCOS patients just during the
Table 1 Main clinical data in cases (PCOS group) and controls (control group) at baseline
PCOS group (n. 45) Control group (n. 42) P
Age (yr) 27.9 ± 3.6 28.2 ± 4.2 0.759
BMI (Kg/m
2) 24.5 ± 2.7 24.8 ± 3.0 0.607
WHR 0.8 ± 0.1 0.7 ± 0.1 0.035
Ferriman-Gallwey score 10.1 ± 2.5 5.1 ± 3.6 < 0.001
OGTT
AUCglucose (mg/dL/120 min) 1012.1 ± 51.6 1061.7 ± 99.4 0.005
AUCinsulin (μU/mL/120 min) 8698.0 ± 2715.9 3898.5 ± 1895.5 < 0.001
AUCglucose/AUCinsulin ratio 0.13 ± 0.01 0.25 ± 0.14 < 0.001
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group; °p < 0.05 vs. baseline and 12
th gestational week.
Figure 2 SHBG and FAI recorded at different times throughout pregnancy in PCOS and control groups.* p < 0.05 vs. control group; ^p <
0.05 vs. previous follow-up; °p < 0.05 vs. baseline and 12
th gestational week.
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pregnancy data regarding insulin resistance was not
available in our sample, even if it is likely to hypothesize
that insulin levels were higher in PCOS subjects than in
healthy controls also before pregnancy. Nevertheless,
both insulin resistance and hyperandrogenism are clini-
cal features of PCOS before and during pregnancy, and
could be implicated in the development of pregnancy
complications. The right timing for these processes are
not still clarified and should be further investigated.
In the current study, the potential androgens and
insulin sensitivity changes throughout pregnancy were
studied in PCOS as well as in healthy women. To this
regard, we performed a parallel analysis of a larger pre-
viously published clinical study [2], reporting data on
hyperandrogenemia and insulin resistance available in
the first (i.e. at study entry and at 12
th weeks of preg-
nancy), the second (i.e. 20
th weeks of pregnancy), and
the third (i.e. 32
nd weeks of pregnancy) trimester of
pregnancy.
As expected considering the original population and
other reports [10-14], PCOS patients were more hyper-
androgenic and insulin resistant than healthy controls at
study entry. These differences were maintained later
throughout pregnancy.
Interesting data rose from the study of the dynamic of
the androgens and insulin-resistance indexes. In agree-
ment with our results, Sir-Peterman et al. [14] pre-
viously showed that PCOS women had significantly
higher concentrations of serum androgen levels than
non-PCOS women. Moreover, similar profile of andro-
gen concentrations and other sexual steroids during
pregnancy in PCOS and healthy women was described
by the same authors [14] suggesting the ovarian origin
of the androgens, although a placental source cannot be
totally discarded. On the contrary, in the current study,
significant increases in serum T and DHEAS levels were
detected only in women affected by PCOS during the
second trimester of pregnancy, and such trend was sus-
tained in the late pregnancy.
Figure 3 Insulin sensitivity indexes at different times throughout pregnancy in PCOS and control groups.* p < 0.05 vs. control group;
°p < 0.05 vs. baseline and 12
th gestational week.
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clear. However, controversial data [15-18] are available
in literature regarding the pathogenetic implications of
hyperandrogenemia during pregnancy on the complica-
tions development. In particular, a significant associa-
tion between circulating maternal T levels and reduced
birth weight was previously shown [12,19]. To this
regard, meta-analytic data reported a lower birth
weight in the most common hyperandrogenic condi-
tion, such as PCOS women. In the current study, a sig-
nificant difference in birth weight was also reported
between PCOS and healthy women. Several potential
mechanisms could be involved, i.e. maternal energy
homeostasis changes, reduction of nutrient transport
through placenta, and direct effect of hyperandrogen-
ism on the fetal growth.
Several authors [15,16] reported high androgen levels
in women with pre-eclampsia. In fact, androgens could
mediate hemodynamic changes underlying pre-eclampsia
development by inducing a state of sympathetic hyperac-
tivity and vascular hyperactivity [20]. To this regard, in
the current, such as in previous studies [1,2], a higher
rate of pre-eclampsia and pregnancy-induced hyperten-
sion has been reported in PCOS women.
Notwithstanding the increase in androgen levels
observed in the current study, a reduced bioavailability
of androgens was found in pregnant PCOS such as in
healthy women. In fact, due to the liver induction of
Table 2 Variations in serum androgen levels and in insulin sensitivity indexes in the general and sub-populations
distinguished on the basis of the presence/absence of adverse obstetric outcomes
Group PCOS group Control group
Total
population
Adverse
outcome
No adverse
outcome
Total
population
Adverse
outcome
No adverse
outcome
T (ng/mL)
Δ(0-12) 0.11 ± 0.02* 0.15 ± 0.01° 0.05 ± 0.02 0.03 ± 0.001 0.04 ± 0.003 0.03 ± 0.002
Δ(0-20) 0.22 ± 0.01* 0.29 ± 0.02° 0.16 ± 0.01 0.02 ± 0.002 0.03 ± 0.002 0.02 ± 0.004
Δ(0-32) 0.31 ± 0.02* 0.36 ± 0.01° 0.24 ± 0.01 0.02 ± 0.001 0.03 ± 0.002 0.02 ± 0.004
A (ng/mL)
Δ(0-12) 0.16 ± 0.01 0.17 ± 0.01 0.17 ± 0.02 0.13 ± 0.01 0.16 ± 0.01 0.12 ± 0.04
Δ(0-20) 0.44 ± 0.02 0.43 ± 0.02 0.45 ± 0.02 0.22 ± 0.01 0.20 ± 0.04 0.23 ± 0.03
Δ(0-32) 0.74 ± 0.01 0.74 ± 0.01 0.74 ± 0.02 0.25 ± 0.01 0.25 ± 0.03 0.24 ± 0.01
DHEAS (ng/mL)
Δ(0-12) 32.25 ± 2.51* 35.69 ± 2.1° 28.97 ± 2.8 10.51 ± 2.16 11.01 ± 2.31 9.43 ± 2.77
Δ(0-20) 175.11 ± 4.92* 184.63 ± 5.2° 166.87 ± 4.5 9.70 ± 1.97 11.26 ± 2.05 9.04 ± 2.52
Δ(0-32) 185.28 ± 6.42* 193.33 ± 6.13° 172.54 ± 6.98 11.34 ± 2.43 12.12 ± 3.06 9.90 ± 2.28
SHBG (nmol/L)
Δ(0-12) 10.71 ± 3.15* 7.48 ± 3.51° 14.13 ± 4.24 26.76 ± 8.34 25.43 ± 8.96 27.61 ± 7.56
Δ(0-20) 90.36 ± 9.44* 73.55 ± 8.34° 116.45 ± 9.08 141.37 ± 9.21 139.12 ± 12.02 153.11 ± 8.42
Δ(0-32) 93.69 ± 8.81* 72.79 ± 7.53° 119.81 ± 8.90 275.18 ± 12.88 268.07 ± 11.32 282.16 ± 13.02
FAI (%)
Δ(0-12) -1.13 ± 0.73* -0.69 ± 0.34° -1.54 ± 0.77 -2.53 ± 0.47 -2.47 ± 0.29 -2.59 ± 0.42
Δ(0-20) -0.92 ± 0.51* -0.12 ± 0.09° -1.88 ± 0.54 -3.13 ± 0.62 -2.99 ± 0.89 -3.23 ± 0.55
Δ(0-32) -1.01 ± 0.90* -0.35 ± 0.06° -1.73 ± 0.49 -3.35 ± 0.51 -3.19 ± 1.01 -3.42 ± 0.47
Fasting insulin (μU/
mL)
Δ(0-12) 1.93 ± 0.36* 2.10 ± 0.21° 1.24 ± 0.43° 1.02 ± 0.52 1.26 ± 0.73 0.98 ± 0.36
Δ(0-20) 2.64 ± 1.13* 2.98 ± 1.05° 2.12 ± 1.02° 1.41 ± 0.24 1.58 ± 0.89 1.14 ± 0.41
Δ(0-32) 2.71 ± 1.55* 3.12 ± 1.23° 2.31 ± 1.51° 1.85 ± 0.73 2.22 ± 0.93 1.44 ± 0.67
GIR (mg/10
-4U)
Δ(0-12) 0.34 ± 0.01* 0.22 ± 0.01° 0.41 ± 0.01 0.12 ± 0.03 0.09 ± 0.01 0.18 ± 0.02
Δ(0-20) 1.02 ± 0.03* 0.78 ± 0.04° 1.76 ± 0.02 0.13 ± 0.05 0.10 ± 0.01 0.17 ± 0.05
Δ(0-32) 1.33 ± 0.06* 1.02 ± 0.02° 1.64 ± 0.01 0.25 ± 0.03 0.20 ± 0.04 0.30 ± 0.01
HOMA
Δ(0-12) 0.62 ± 0.01* 0.84 ± 0.02° 0.46 ± 0.01 -0.18 ± 0.04 -0.20 ± 0.05 -0.10 ± 0.03
Δ(0-20) 0.91 ± 0.04* 1.02 ± 0.03° 0.86 ± 0.02 -0.27 ± 0.12 -0.37 ± 0.15 -0.18 ± 0.10
Δ(0-32) 1.12 ± 0.06* 1.48 ± 0.05° 0.89 ± 0.03 -0.26 ± 0.06 -0.34 ± 0.05 -0.19 ± 0.06
*p < 0.05 vs. control group; °p < 0.05 vs. no adverse outcome.
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start. Thus, other factors, mainly related to insulin resis-
tance impairment, cannot be excluded in generating
pregnancy complications in PCOS. In fact, the insulin
resistance indexes measured were worsened at the sec-
ond and third trimester of pregnancy in our sample of
non-obese PCOS patients when compared to healthy
controls with similar age and BMI.
Insulin resistance could be per se sufficient to induce
endothelial dysfunction directly or indirectly through
multiple pathways, and thus predispose cardiovascular
disease and to major pregnancy complications in the
third trimester, including pre-eclampsia and IUGR [21].
In particular, even if not always demonstrated [22], sev-
eral data [23-26] supported the association between
insulin resistance and subsequent pre-eclampsia. In par-
ticular, two prospective studies [23,24] showed an
increased risk of pre-eclampsia in women with impaired
insulin resistance during the second trimester of preg-
nancy. Similarly, more recent data [25,26] remarked an
association also between first trimester insulin resistance
and subsequent pre-eclampsia. In fact, insulin resistance,
in concert with other contributing factors, including
hyperandrogenism [27], inflammation [28] and increased
weight gain [29], seems to impair the trophoblastic/pla-
cental angiogenesis and to be a causative factor for pre-
eclampsia development.
Finally, in order to evaluate the effects of the changes
in androgens and insulin sensitivity indexes throughout
pregnancy on the pregnancy and/or neonatal outcomes,
a sub-analysis of our sample according to the presence/
absence of complicated pregnancy was performed.
Although on a very small sample, our data on PCOS
women confirmed previous report on pregnant women
without a specific diagnosis of PCOS [15-18]. In fact,
PCOS women who had a complicated pregnancy were
more hyperandrogenic and insulin resistant throughout
pregnancy in comparison with those who had not a
pregnancy complications. Moreover, the dynamic during
pregnancy of serum T, DHEAS, SHBG, FAI, fasting
insulin, GIR and HOMA differed significantly according
to the pregnancy outcomes showing an impairment of
androgen and free androgen levels and insulin resistance
markers. On the other hand, no relevant differences
were obtained in our healthy population between sub-
jects who had a worse pregnancy outcome in compari-
son with those who had not any adverse outcome.
Conclusions
PCOS patients have impaired changes in serum andro-
gen levels and insulin sensitivity indexes during preg-
nancy. These alterations could be implicated in
pregnancy and neonatal complications frequently
observed in women affected by PCOS. Further data
deriving from well-powered studies would be necessary
in order to confirm the relationship between hormonal
and metabolic dynamic during pregnancy and risk of
pregnancy complications in women affected by PCOS,
and in order to clarify the specific pathogenetic
mechanisms.
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